BriaCell Therapeutics - Warrants (24/02/2025) Return on Equity

BriaCell Therapeutics - Warrants (24/02/2025)'s return on equity stands at -131.04%. That is below the Healthcare sector average of 22.01%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

BriaCell Therapeutics - Warrants (24/02/2025) sits lower the Healthcare benchmark (22.01%) with a ROE of -131.04%. That is roughly 695.4% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of -131.04% for BriaCell Therapeutics - Warrants (24/02/2025) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how BriaCell Therapeutics - Warrants (24/02/2025)'s ROE evolved across reporting periods, while the comparison chart places BCTXW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. BriaCell Therapeutics - Warrants (24/02/2025)'s reading of -131.04% (sector avg 22.01%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.